Abstract
The objective of the study was to assess the feasibility of using CA -62 marker of epithelial carcinomas for monitoring treatment response and detecting cancer progression or recurrence during chemotherapy.Material and Methods. A 12-month double-blind clinical trial was conducted by two independent groups: clinical oncologists and biochemists, and involved 89 patients with different cancers confirmed by histopathological findings. The other inclusion criteria were: the presence of at least one measurable lesion according to the RECIST criteria, ECOG performance status 0-2 and satisfactory laboratory parameters. The expression of CA -62 cancer marker was measured by immunochemiluminescent assay used for the detection of epithelial carcinomas.Results. The elevated level of CA -62 marker was observed in 76 patients before starting the treatment. After completion chemotherapy, the level of this marker decreased to the normal reference ranges (<4600 U/ml) in 53 % of patients and remained increased in 24 % of patients. Of 24 % of patients with the initial low level of CA -62 marker (1000–4000 U/ml) before treatment, 12 % had no changes in the level of this marker during chemotherapy; however, 5 % of these patients had disease progression and 7 % had stable disease after starting the treatment. In 12 % of patients with an initial low CA -62 level, it increased during chemotherapy, indicating disease progression.Conclusion. The changes in the level of CA -62 marker during chemotherapy in patients with gastric cancer, small-cell lung cancer, colorectal cancer, neuroendocrine cancer and ovarian cancer showed a high correlation (76–100 % depending on the tumor site) with the performance status of the patients according to RECIST criteria. The CA -62 marker was shown to be feasible for monitoring gastric cancer, small-cell lung cancer, colorectal cancer, neuroendocrine cancer and ovarian cancer as well as for assessing the response to chemotherapy.
Highlights
Многочисленные клинические исследования, проведенные в России, Европе, Канаде и США [4,5,6,7,8,9,10,11,12], определили некоторые перспективные биомаркеры, способные выявлять в отдельных случаях рецидивы, прогнозировать течение опухолевого процесса, а также предсказывать ответ опухоли на проводимое лекарственное лечение
The objective of the study was to assess the feasibility of using CA-62 marker of epithelial carcinomas for monitoring treatment response and detecting cancer progression or recurrence during chemotherapy
The expression of CA-62 cancer marker was measured by immunochemiluminescent assay used for the detection of epithelial carcinomas
Summary
Для цитирования: Хакимова Г.Г., Черкасова Ж.Р., Цуркан С.А., Федчиков Г.А., Суганов Н.В., Горбунова В.А. Пилотное клиническое исследование по мониторингу эффективности химиотерапии злокачественных опухолей у пациентов с помощью маркера эпителиальных карцином СА-62. For citation: Khakimova G.G., Cherkasova Zh.R., Tsurkan S.А., Fedchikov G.А., Suganov N.V., Gorbunova V.А. A pilot clinical trial to monitor response to chemotherapy using the CA-62 marker of epithelial carcinomas.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
